Perivascular spaces are associated with tau pathophysiology and synaptic dysfunction in early Alzheimer's continuum.
Alzheimer’s disease
CSF biomarkers
MRI
Perivascular spaces
Tau pathophysiology
Virchow-Robin spaces
Journal
Alzheimer's research & therapy
ISSN: 1758-9193
Titre abrégé: Alzheimers Res Ther
Pays: England
ID NLM: 101511643
Informations de publication
Date de publication:
05 08 2021
05 08 2021
Historique:
received:
30
09
2020
accepted:
21
07
2021
entrez:
6
8
2021
pubmed:
7
8
2021
medline:
14
8
2021
Statut:
epublish
Résumé
Perivascular spaces (PVS) have an important role in the elimination of metabolic waste from the brain. It has been hypothesized that the enlargement of PVS (ePVS) could be affected by pathophysiological mechanisms involved in Alzheimer's disease (AD), such as abnormal levels of CSF biomarkers. However, the relationship between ePVS and these pathophysiological mechanisms remains unknown. We aimed to investigate the association between ePVS and CSF biomarkers of several pathophysiological mechanisms for AD. We hypothesized that ePVS will be associated to CSF biomarkers early in the AD continuum (i.e., amyloid positive cognitively unimpaired individuals). Besides, we explored associations between ePVS and demographic and cardiovascular risk factors. The study included 322 middle-aged cognitively unimpaired participants from the ALFA + study, many within the Alzheimer's continuum. NeuroToolKit and Elecsys® immunoassays were used to measure CSF Aβ42, Aβ40, p-tau and t-tau, NfL, neurogranin, TREM2, YKL40, GFAP, IL6, S100, and α-synuclein. PVS in the basal ganglia (BG) and centrum semiovale (CS) were assessed based on a validated 4-point visual rating scale. Odds ratios were calculated for associations of cardiovascular and AD risk factors with ePVS using logistic and multinomial models adjusted for relevant confounders. Models were stratified by Aβ status (positivity defined as Aβ42/40 < 0.071). The degree of PVS significantly increased with age in both, BG and CS regions independently of cardiovascular risk factors. Higher levels of p-tau, t-tau, and neurogranin were significantly associated with ePVS in the CS of Aβ positive individuals, after accounting for relevant confounders. No associations were detected in the BG neither in Aβ negative participants. Our results support that ePVS in the CS are specifically associated with tau pathophysiology, neurodegeneration, and synaptic dysfunction in asymptomatic stages of the Alzheimer's continuum.
Sections du résumé
BACKGROUND
Perivascular spaces (PVS) have an important role in the elimination of metabolic waste from the brain. It has been hypothesized that the enlargement of PVS (ePVS) could be affected by pathophysiological mechanisms involved in Alzheimer's disease (AD), such as abnormal levels of CSF biomarkers. However, the relationship between ePVS and these pathophysiological mechanisms remains unknown.
OBJECTIVE
We aimed to investigate the association between ePVS and CSF biomarkers of several pathophysiological mechanisms for AD. We hypothesized that ePVS will be associated to CSF biomarkers early in the AD continuum (i.e., amyloid positive cognitively unimpaired individuals). Besides, we explored associations between ePVS and demographic and cardiovascular risk factors.
METHODS
The study included 322 middle-aged cognitively unimpaired participants from the ALFA + study, many within the Alzheimer's continuum. NeuroToolKit and Elecsys® immunoassays were used to measure CSF Aβ42, Aβ40, p-tau and t-tau, NfL, neurogranin, TREM2, YKL40, GFAP, IL6, S100, and α-synuclein. PVS in the basal ganglia (BG) and centrum semiovale (CS) were assessed based on a validated 4-point visual rating scale. Odds ratios were calculated for associations of cardiovascular and AD risk factors with ePVS using logistic and multinomial models adjusted for relevant confounders. Models were stratified by Aβ status (positivity defined as Aβ42/40 < 0.071).
RESULTS
The degree of PVS significantly increased with age in both, BG and CS regions independently of cardiovascular risk factors. Higher levels of p-tau, t-tau, and neurogranin were significantly associated with ePVS in the CS of Aβ positive individuals, after accounting for relevant confounders. No associations were detected in the BG neither in Aβ negative participants.
CONCLUSIONS
Our results support that ePVS in the CS are specifically associated with tau pathophysiology, neurodegeneration, and synaptic dysfunction in asymptomatic stages of the Alzheimer's continuum.
Identifiants
pubmed: 34353353
doi: 10.1186/s13195-021-00878-5
pii: 10.1186/s13195-021-00878-5
pmc: PMC8340485
doi:
Substances chimiques
Amyloid beta-Peptides
0
Biomarkers
0
Membrane Glycoproteins
0
Receptors, Immunologic
0
TREM2 protein, human
0
alpha-Synuclein
0
tau Proteins
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
135Subventions
Organisme : European Research Council
ID : 681712
Pays : International
Investigateurs
Annabella Beteta
(A)
Anna Brugulat
(A)
Raffaele Cacciaglia
(R)
Alba Cañas
(A)
Carme Deulofeu
(C)
Irene Cumplido
(I)
Ruth Dominguez
(R)
Maria Emilio
(M)
Karine Fauria
(K)
Sherezade Fuentes
(S)
Laura Hernandez
(L)
Gema Huesa
(G)
Jordi Huguet
(J)
Paula Marne
(P)
Tania Menchón
(T)
Albina Polo
(A)
Sandra Pradas
(S)
Blanca Rodriguez-Fernandez
(B)
Aleix Sala-Vila
(A)
Gonzalo Sánchez-Benavides
(G)
Gemma Salvadó
(G)
Anna Soteras
(A)
Marc Vilanova
(M)
Informations de copyright
© 2021. The Author(s).
Références
Sci Rep. 2019 Dec 13;9(1):19024
pubmed: 31836810
J Am Heart Assoc. 2020 Aug 18;9(16):e015229
pubmed: 32805190
Brain Pathol. 2015 Jan;25(1):63-78
pubmed: 25521178
Oncotarget. 2017 Jul 4;8(27):44477-44489
pubmed: 28574812
AJNR Am J Neuroradiol. 1989 Sep-Oct;10(5):929-36
pubmed: 2505536
Cerebrovasc Dis. 2015;39(3-4):224-31
pubmed: 25823458
Alzheimers Dement. 2020 Oct;16(10):1358-1371
pubmed: 32573951
Neuroimage Clin. 2020;25:102120
pubmed: 31887717
Lancet Neurol. 2006 Sep;5(9):735-41
pubmed: 16914401
Int J Stroke. 2019 Jun;14(4):359-371
pubmed: 30762496
Alzheimers Dement (N Y). 2016 Mar 03;2(2):82-92
pubmed: 29067295
Nat Neurosci. 2017 Feb;20(2):170-172
pubmed: 27991899
J Neuroimaging. 2018 Mar;28(2):139-149
pubmed: 29280227
Neuron. 2017 Dec 6;96(5):1024-1032.e3
pubmed: 29216449
Alzheimers Dement. 2018 Apr;14(4):535-562
pubmed: 29653606
Lancet Neurol. 2013 Aug;12(8):822-38
pubmed: 23867200
Stroke. 2010 Nov;41(11):2483-90
pubmed: 20864661
Surg Neurol Int. 2016 Oct 07;7(Suppl 26):S711-S714
pubmed: 27857861
Nat Rev Neurol. 2020 Mar;16(3):137-153
pubmed: 32094487
Alzheimers Dement. 2018 Jul;14(7):902-912
pubmed: 29605385
Eur J Hum Genet. 2014 Oct;22(10):1239-42
pubmed: 24448547
Clin Biochem. 2019 Oct;72:30-38
pubmed: 31129184
JAMA Neurol. 2019 Jan 1;76(1):81-94
pubmed: 30422209
Rev Esp Salud Publica. 2012 Oct;86(5):495-508
pubmed: 23223762
J Alzheimers Dis. 2013;33(2):323-8
pubmed: 22976070
Brain. 2008 Sep;131(Pt 9):2332-40
pubmed: 18676439
Radiographics. 2007 Jul-Aug;27(4):1071-86
pubmed: 17620468
PLoS One. 2014 Aug 26;9(8):e105505
pubmed: 25157843
J Prev Alzheimers Dis. 2021;8(1):68-77
pubmed: 33336227
JAMA Neurol. 2017 Sep 1;74(9):1105-1112
pubmed: 28715552
PLoS One. 2015 Sep 09;10(9):e0137323
pubmed: 26352265
Alzheimers Res Ther. 2019 Apr 22;11(1):34
pubmed: 31010420
J Alzheimers Dis. 2018;66(4):1587-1597
pubmed: 30475760